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Objectives: Development of an efficacious vaccine against brucellosis has been a
challenge for scientists for many years. At present, there is no licensed vaccine
against human brucellosis. To overcome this problem, currently, antigenic de-
terminants of Brucella cell wall such as Lipopolysaccharide (LPS) are considered
as potential candidates to develop subunit vaccines.
Methods: In this study, Brucella abortus LPS was used for conjugation to Neis-
seria meningitidis serogroup B outer membrane vesicle (OMV) as carrier protein
using carbodiimide and adipic acidemediated coupling and linking, respectively.
Groups of eight BALB/c mice were injected subcutaneously with 10 mg LPS alone,
combined LPS + OMV and conjugated LPSeOMV on 0 days, 14 days, 28 days and 42
days. Anti-LPS IgG was measured in serum.
Results: The yield of LPS to OMV in LPSeOMV conjugate was 46.55%, on the basis
of carbohydrate content. The ratio for LPS to OMV was 4.07. The LPSeOMV
conjugate was the most immunogenic compound that stimulated following the
first injection with increased IgG titer ofw5-fold andw1.3-fold higher than that
produced against LPS and LPS in noncovalent complex to OMV (LPS + OMV),
respectively. The highest anti-LPS IgG titer was detected 2 weeks after the third
injection (Day 42) of LPSeOMV conjugate. The conjugated compound elicited), karbasian.m@gmail.com (A. Karbasian).
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10 S.D. Siadat, et alhigher titers of IgG than LPS + OMV, that showed a 100e120-fold rise of anti-LPS
IgG in mice.
Conclusion: These results indicate that our conjugated LPSeOMV can be used as
a brucellosis vaccine, but further investigation is required.1. Introduction
Brucellosis is one of the common bacterial zoonoses
caused by organisms belonging to genus Brucella, a
Gram-negative, non-spore-forming, facultative intra-
cellular bacterium. Development of an efficacious
vaccine against brucellosis has been a challenge for
scientists for many years [1]. At present, there is no
licensed vaccine against human brucellosis. To over-
come this problem, currently, antigenic determinants
of Brucella cell wall such as lipopolysaccharide (LPS)
are considered as potential candidates for the devel-
opment of subunit vaccines. Also, Brucella abortus
LPS is considered as one of the most important anti-
gens from the point of view of the primary targets of
the innate immunity. The LPS of smooth strains of
Brucella spp. comprise lipid A, fatty acids, a core re-
gion, and a polysaccharide O-side chain. The lipid A
moiety alone is sufficient to activate the innate immune
response; adaptive (antibody) responses are generated
to the O antigen polysaccharide later in the course of
infection [2].
Naturally occurring strains lacking LPS show
reduced survival, therefore, LPS is considered to be a
major virulence factor. Previous studies have clearly
established that Smooth lipopolysaccharide is necessary
for efficient intracellular survival and virulence of
Brucella melitensis, B. abortus and Brucella suis. B.
abortus S-LPS is 100 times less potent than that of
Escherichia coli and Salmonella in inducing tumor ne-
crosis factor g produced by macrophages, as well as
oxidative metabolism and lysozyme release by human
neutrophils. This feature of S-LPS has been proposed to
contribute to the survival of B. abortus within phago-
cytic cells. In addition, Brucella S-LPS is not suscepti-
ble to the actions of polycationic molecules, suggesting
that smooth Brucella can resist the cationic bactericidal
peptides of the phagocytes. S-LPS has also been found
to confer antiphagocytic properties upon Brucella and is
unable to activate the alternative pathway of the com-
plement cascade [1e3].
It has been documented that polysaccharide (from
bacterial capsule or LPS)eprotein conjugates are usu-
ally immunogens in mice, rabbits and humans [4,5].
Many studies have shown that these conjugated vaccines
can elicit humoral and cellular immunity against many
human pathogens including Neisseria meningitidis,
Vibrio cholerae, Haemophilus influenzae, Shigella son-
nei, as well as Brucella spp. [4e7]. Covalent linkage of
the polysaccharide, or fractions thereof, to immunogeniccarriers (i.e., proteins) creates glycoconjugates that are
T-dependent antigens and prime for boosting either with
the glycoconjugate or the LPS. In contrast, poly-
saccharide or LPSeprotein conjugate has been proven to
be effective in several cases, and well-defined glyco-
conjugate vaccines have also been explored with a view
to elicit discriminating immune responses [2,7,8]. Jac-
ques et al showed the efficacy of Brucella O-poly-
saccharideeBSA conjugate in protection against B.
melitensis H38 [9]. Other studies have been carried out
to design subunit vaccines using other components and
conjugated compounds such as porins and smooth
lipopolysaccharide, recombinant ribosomal proteins and
anti-OPS specific monoclonal antibodies [10e12].
The outer membrane vesicle (OMV) of N. menin-
gitidis is among the newly studied components of
microbial origin, which could be applied as a novel
carrier. In addition, the potency of OMV as a carrier
(conjugated to a hapten) is now proven. Overall, pre-
vious studies have shown that the predominant outer
membrane proteins (PorA, PorB and RmpM) from N.
meningitidis present in the Meningococci B Cuban
vaccine had different capacities to prime the immune
responses [1,13e16].
In the present study, we designed a subunit brucel-
losis vaccine composed of B. abortus S99 LPS with N.
meningitidis serogroup B OMV as a covalent conjugate
and then evaluated specific antibody response against
the LPS of B. abortus S99.2. Materials and methods
2.1. Bacterial strain, culture and fermentation
conditions
B. abortus S99 was obtained from the Collection of
Standard Bacteria, Pasteur Institute of Iran. This strain of
B. abortus (biovar1) is smooth and CO2 independent. It
was cultured in slant Brucella agar medium (Merck,
Germany) at 37 1C for 72 hours and then cultured in a
5-L flask containing 2 L Brucella broth (Merck) under
aeration by a sparger at 37 1C for 72 hours to achieve
the seed culture. Seed culture inoculated to the 60-L in-
dustrial fermenter (Novapaljas, contact-flow B.V,
Netherlands) with a 40-L working volume [2]. The tem-
perature and pH were adjusted to 37  1C and 6.4,
respectively. Finally, after 60 hours, the fermentation
process stopped by adding 10% phenol to the fermenta-
tion culture and biomass of B. abortus S99 harvested by
centrifugation (1,19).
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chemical analysis
As described previously, B. abortus S99 LPS was
extracted by an optimized method based on hot phe-
nolewater and the extracted sample was chemically
analyzed to define the content of LPS, 2-keto-3-
deoxyoctonate, protein and nucleic acids (1,19).2.3. Preparation of OMVs
OMVswere prepared as previously described [2,6,14].
N. meningitidis serogroup B strain CSBPI and G-245
cells were grown in 40 L modified Frantz medium in a
fermenter for 24 hours at 36C. The OMV was extracted
from the cells by the method of Claassen et al [2,6,14].2.3.1. Synthesis of LPSeOMV conjugates
LPS derivatives of B. abortus S99 were conjugated
with N. meningitidis serogroup B OMV using adipic
acid dihydrazide (ADH) as linker and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDAC) as
coupling reagent [8,14e17]. ADH was conjugated to
LPS (96 mg) in 12 mL 287mM ADH suspension to form
adipic hydrazide (AH)eLPS derivatives, using EDAC
HCl and N-hydroxysulfosuccinimide. The resulting
AHeLPS was finally coupled to OMV. Ten milligrams
of OMV was reacted with 20 mg AHeLPS (10 mg/mL)
using 0.05M 1-ethyl-3-(3-dimethylaminopropyl) carbo-
diimide HCl. The reaction mixtures were maintained at
pH 5.0e5.2 for 4 hours at 4C, and the reactions were
stopped by adjusting the pH to 7.0. The reaction mix-
tures were dialyzed against 0.9% NaCl for 2e3 days,
centrifuged, and passed through a Sephacryl S-300
column (2.6 cm  90 cm) in 0.9% NaCl. The peaks that
contained both protein and carbohydrate were pooled
and designated LPSeOMV. The conjugate was
analyzed to determine the carbohydrate and protein
contents using LPS and bovine serum albumin as stan-
dards [8,18].2.4. Limulus amebocyte lysate assay
The LPS was tested to determine its endotoxin
reactivity using a Limulus amebocyte lysate (LAL)
Pyrogent Plus reagent kit (24 single test vials; Bio-
whittaker, Walkersville, MD, USA). The sensitivity of
the LAL assay was 0.12 endotoxin unit (EU)/mL [13].2.4.1. Immunization procedures
Groups of eight female BALB/c mice were injected
subcutaneously four times at 2-week intervals with
LPSeOMV conjugate (10 mg LPS in polysaccharide
content), LPS þ OMV (10 mg S-LPS plus 50 mg OMV)
and LPS (10 mg polysaccharide) in 0.2 mL 0.9% NaCl.
The immunized animals were bled prior to injection and
2 weeks after each injection [2].2.4.2. Enzyme-linked immunosorbent assay
Specific antibody molecules produced against the
extracted LPS of B. abortus were demonstrated by
enzyme-linked immunosorbent assay (ELISA). Total
specific IgG molecules, elicited against the S-LPS of B.
abortus were detected. ELISA was performed in 96-well
flat-bottom polystyrene microtiter plates. The wells
were coated with the extracted S-LPS of B. abortus S99
at a concentration of 10 mg/mL in phosphate-buffered
saline (PBS) azide (0.014M NaCl, 0.02% sodium
azide, 0.01M sodium phosphate; pH 7.5) and incubated
overnight at 37C. The wells were washed three times
with PBS azide. The wells were blocked by adding
blocking buffer (1% casein in PBSeazide) and then
incubated again at 37C for 1 hour. Serial twofold di-
lutions of the sera were made on the plates. The plates
were maintained at 25C for 16 hours. Horseradish-
peroxidase-labeled goat anti-mouse IgG was added to
the wells at a concentration of 1 mg/mL and the plates
were incubated at 25C for 16 hours. Afterwards, the
substrate of horseradish peroxidase (3,30,5,50-Tetrame-
thylbenzidine) was added to the wells at a concentration
of 1 mg/mL and the plates were incubated at room
temperature for 30 minutes. Finally, stop solution
(50 mL) was added to the wells and absorbance was
measured at 405 nm using an automatic ELISA plate
reader. The antibody titers are expressed in OD units
and calculated by multiplying the reciprocal dilution of
the serum by the OD at that dilution [2].
2.4.3. Statistical methods
Antibody titers of groups of mice were expressed as
means  standard deviations. The significance of differ-
ences in ELISA titers was determined by Student’s t test.3. Results
3.1. Fermentation process
The efficiency of the fermentation process to obtain
B. abortus S99 biomass was satisfactory because the cell
density and count of viable cells were 8.9% and
3.1  1011, respectively. At the end of the fermentation
process, microscopic evaluation to determine microbial
content was carried out and the purity of resulting
biomass was confirmed.
3.2. LPS characterization
LPSwas isolatedusing the optimized hot phenolewater
extraction method. The LPS concentration was 146 EU/
mL.TheLPS content of the extracted sample (measured by
chromogenic LAL assay) was 108 EU/mL. The 2-keto-3-
deoxyoctonate content (measured by Weisbach method)
was 1.3%. In addition, the protein content of the sample
(measured by picodrop) was < 2.0, and the nucleic acid
content was < 1%.
Table 1. Anti-Brucella abortus S99 LPS total IgG titer  standard deviation, 2 weeks after the first, second and third
injections.
Compound
Anti-B. abortus S99 LPS
IgG titer, 2 wk after
first injection
Anti-B. abortus S99 LPS IgG titer,
2 wk after second
(first booster) injection
Anti-B. abortus S99 LPS
IgG titer, 2 wk after third
(second booster) injection
LPS 1,868  106 6,828  577 16,809  1,276
LPS þ OMV 7,398  390 45,057  2,779 91,993  5,665
Conjugated LPSeOMV 9,386  480 67,280  2,539 112,978  4,356
Control group (normal saline) <3 <3 <3
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The ratio of the conjugates obtained in three experi-
ments were similar, obtaining them with an average
LPS/OMV ratio of 4.07. On the basis of carbohydrate,
the yield of LPS to OMV in LPSeOMV conjugate was
46.55% content.
3.4. ELISA
Subcutaneous administration of B. abortus S99 LPS
increased specific anti-LPS IgG titer in all the groups.
Among the three injected compounds, LPSeOMV
conjugate was the most immunogenic compound, pro-
moting produced IgG titer following the first injection,
which was fivefold and 1.3-fold higher than IgG titer
elicited against LPS and LPS þ OMV, respectively. The
booster injections (especially the first booster) signifi-
cantly increased the titer of anti-B. abortus S99 LPS IgG
in all the groups (p < 0.05). The first and second booster
injections of LPSeOMV conjugate caused 7.2-fold and
12-fold higher titers compared to the anti-LPS IgG titer
induced after the first injection. The highest anti-LPS
IgG titer was detected 2 weeks after the third injection
(Day 42) of LPSeOMV conjugate (Table 1).4. Discussion
We synthesized an LPSeOMV conjugate that was
immunogenic in mice. This conjugate showed good
antigenicity in vitro and elicited high levels of serum
anti-LPS IgG in mice. The conjugated LPS elicited
higher titers of anti-LPS IgG than LPS þ OMV elicited,
which showed a 1.2-fold rise of anti-LPS IgG in mice.
These data are for the most part consistent with our
previous studies with complex of B. abortus S99 LPS
with N. meningitidis OMV. Our previous studies had
demonstrated that LPS þ OMV was immunogenic in
mice and elicited a high level of anti-LPS IgG titers [2].
In this study, the conjugated LPS retained antigenic
determinants when covalently bound to protein carriers.
These data show that the use of a basic hydrolysis for the
activation of LPS and the later use of EDAC for acti-
vation of OMV yields a conjugated compound that can
elicit high levels of anti-LPS IgG in mice. At the same
time, the data indicated that the carrier protein, in theform of an intact OMV, is an important factor for in-
duction immunogenicity where the LPS component has
to be protected.
Many studies have shown that polysaccharide (from
bacterial capsule or LPS) or LPSeprotein conjugates are
usually effective immunogens in mice and rabbits as well
as in humans. Regarding the use ofLPS as a component for
conjugates, many factors may result in differences of
antibody response generated in vivo. These include the
composition of conjugate, protein carrier, immunization
routes, adjuvants, animal species, and detection methods
[14]. Yu et al designed LPS-based conjugate vaccines and
reported the serumbactericidal activity of these conjugates
in rabbits andmice [4,5]. Inmeningococcal LPS conjugate
studies, Jening et al showed that oligosaccharide-tetanus
toxoid conjugates, elicited bactericidal antibodies in rab-
bits to the homologus strains [20e22]. In the same study,
we synthesized the group A capsular poly-
saccharideeOMV of meningococci serogroup B conju-
gate and showed the serum bactericidal activity of this
conjugate in rabbits [6,8].
As mentioned earlier, anti-B. abortus S99 LPS IgG
titers exponentially and significantly increased in all
groups compared to the control group. The high titers of
anti-B. abortus S99 LPS IgG in comparison with the
control group indicate the immunogenicity of B. abortus
S99 LPS and the fidelity of our LPS extraction procedure
which does not interfere with the natural and immuno-
genic structure of LPS. Furthermore, as mentioned above,
during the process of conjugation, the antigenic de-
terminants have been protected in all of the components
(LPS þ OMV).
In conclusion, conjugation of LPS to OMV was
designed and the antigenicity of this conjugate was
evaluated by ELISA. The conjugate elicited higher ti-
ters of IgG than LPS þ OMV elicited, which showed a
120e165-fold rise of anti-LPS IgG in mice. These
results indicate that our conjugated LPS, can be used as
a brucellosis vaccine, but further investigation is
required.Conflicts of interest
Authors declare no conflict of interest.
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